Colchicine for gout flare prevention and familial Mediterranean fever treatment

Colchicine is an oral medication used primarily to prevent and treat gout flares in adults, and to treat familial Mediterranean fever (FMF) in both adults and children aged 4 years and older. It helps reduce inflammation associated with these conditions and is taken as tablets.

Colchicine tablets are approved for the following uses:

• Gout flares: Preventing gout flares (prophylaxis) in adults and adolescents older than 16 years, and treating acute gout flares when taken at the first sign of symptoms.
• Familial Mediterranean fever (FMF): Treatment of FMF in adults and pediatric patients aged 4 years and older.

Colchicine tablets are not recommended for pediatric use in prevention or treatment of gout flares.

Colchicine

Colchicine works by interrupting the inflammatory process involved in gout and familial Mediterranean fever. It reduces the buildup of urate crystals and inflammatory molecules in affected tissues, thereby decreasing swelling and pain.

Gout flare prophylaxis (adults and adolescents >16 years)

0.6 mg orally once or twice daily. Maximum dose: 1.2 mg per day.

Treatment of acute gout flares (adults and adolescents >16 years)

1.2 mg (two tablets) at the first sign of a flare, followed by 0.6 mg (one tablet) one hour later. Maximum dose for treatment: 1.8 mg over 1 hour. If taking prophylaxis, after treatment wait 12 hours before resuming prophylactic dose.

Familial Mediterranean fever (FMF)

Adults: 1.2 to 2.4 mg daily, given as one or two divided doses. Dose adjustments can be made in 0.3 mg increments based on disease control and tolerability.

Children 4–6 years: 0.3 to 1.8 mg daily, single or divided dose.

Children 6–12 years: 0.9 to 1.8 mg daily, single or divided dose.

Adolescents >12 years: 1.2 to 2.4 mg daily, single or divided dose.

Important considerations

• Administer colchicine tablets orally without regard to meals.
• Dose adjustments needed for patients with renal or hepatic impairment and those receiving interacting drugs (CYP3A4 or P-glycoprotein inhibitors).
• Not recommended for pediatric use in gout flare prevention or treatment.
• Prophylactic colchicine may be used for at least 6 months when starting uric acid-lowering therapy to reduce flare risk.

Colchicine tablets are contraindicated in patients with renal or hepatic impairment when used concomitantly with strong CYP3A4 inhibitors or P-glycoprotein inhibitors due to risk of fatal toxicity.

Serious toxicity risks include:

• Fatal colchicine toxicity associated with concomitant use of strong CYP3A4 or P-gp inhibitors in patients with renal or hepatic impairment.
• Increased risk of neuromuscular toxicity when combined with certain CYP3A4 inhibitors like diltiazem and verapamil.
• Caution and dose reduction required in patients with moderate to severe renal or hepatic impairment.
• Avoid using colchicine for gout flare treatment in patients already receiving prophylaxis and CYP3A4 inhibitors.

Careful monitoring is required to detect adverse effects early, especially in patients with impaired kidney or liver function.

Common side effects include gastrointestinal symptoms such as diarrhea, nausea, and abdominal pain. Serious but less common adverse effects include neuromuscular toxicity and bone marrow suppression.

Key drug interactions that increase colchicine toxicity risk:

• Strong CYP3A4 inhibitors: clarithromycin, ketoconazole, ritonavir, atazanavir, indinavir, itraconazole, lopinavir/ritonavir, telithromycin, and others. Concomitant use contraindicated in patients with renal or hepatic impairment.
• Moderate CYP3A4 inhibitors: erythromycin, fluconazole, diltiazem, verapamil. Dose reduction is recommended.
• P-glycoprotein inhibitors: cyclosporine, ranolazine. Dose adjustment required; contraindicated in renal or hepatic impaired patients.

Patients recently or currently treated with these interacting drugs within 14 days require colchicine dose adjustments or avoidance.